Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Thromb Haemost ; 110(3): 569-81, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23784669

ABSTRACT

Following initial platelet activation, arachidonic acid is metabolised by cyclooxygenase-1 and 12-lipoxygenase (12-LOX). While the role of 12-LOX in the platelet is not well defined, recent evidence suggests that it may be important for regulation of platelet activity and is agonist-specific in the manner in which it regulates platelet function. Using small molecule inhibitors selective for 12-LOX and 12-LOX-deficient mice, the role of 12-LOX in regulation of human platelet activation and thrombosis was investigated. Pharmacologically inhibiting 12-LOX resulted in attenuation of platelet aggregation, selective inhibition of dense versus alpha granule secretion, and inhibition of platelet adhesion under flow for PAR4 and collagen. Additionally, 12-LOX-deficient mice showed attenuated integrin activity to PAR4-AP and convulxin compared to wild-type mice. Finally, platelet activation by PARs was shown to be differentially dependent on COX-1 and 12-LOX with PAR1 relying on COX-1 oxidation of arachidonic acid while PAR4 being more dependent on 12-LOX for normal platelet function. These studies demonstrate an important role for 12-LOX in regulating platelet activation and thrombosis. Furthermore, the data presented here provide a basis for potentially targeting 12-LOX as a means to attenuate unwanted platelet activation and clot formation.


Subject(s)
Arachidonate 12-Lipoxygenase/metabolism , Blood Platelets/metabolism , Platelet Membrane Glycoproteins/metabolism , Receptors, Thrombin/metabolism , 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid/chemistry , Animals , Cyclooxygenase 1/metabolism , Eicosanoids/metabolism , Flow Cytometry , Humans , Mice , Mice, Transgenic , Platelet Activation , Platelet Adhesiveness , Platelet Aggregation , Thrombosis/metabolism , Time Factors
2.
Int J Parasitol Drugs Drug Resist ; 2: 171-177, 2012 Dec 01.
Article in English | MEDLINE | ID: mdl-22844653

ABSTRACT

Hookworm disease, characterized by severe anemia and cognitive and growth delays, currently affects an estimated 740 million people worldwide. Despite the prevalence of this parasitic disease, few effective drug therapies are in use today, and the heavy reliance upon benzimidazoles highlights the need for the development of novel chemotherapies. Recent work with the trematode parasite Schistosoma mansoni has identified oxadiazole 2-oxides as effective antischistosomal compounds that function by targeting and inhibiting the antioxidant enzyme, thioredoxin glutathione reductase. In this study, a related enzyme, glutathione reductase, from the human hookworm Ancylostoma ceylanicum was identified and characterized, and its in vitro activity in the presence of the oxadiazole 2-oxides was analyzed. Ex vivo worm killing assays were also conducted to establish the relationship between a given compound's effect upon worm survival and inhibition of recombinant glutathione reductase (rAceGR). Finally, the in vivo anthelminthic efficacy of furoxan (Fx) was assessed in the hamster model of hookworm infection. The predicted amino acid sequence of AceGR contained a prototypical glutathione reductase active site sequence, but no thioredoxin reductase consensus sequences, suggesting that the glutathione and thioredoxin pathways of A. ceylanicum are distinct. Although ten of the forty-two oxadiazole 2-oxides tested inhibited rAceGR activity by at least fifty percent, and fifteen compounds were toxic to parasites ex vivo, little overlap existed between these two results. We therefore suggest that AceGR is not the primary target of the oxadiazole 2-oxides in effecting parasite death. Lastly, oral treatment of A. ceylanicuminfected hamsters with furoxan resulted in significantly improved weight gains and reduced intestinal worm burdens compared to vehicle treated controls, supporting continued development of this molecule as a novel anthelminthic.

4.
Appl Opt ; 32(12): 2152-8, 1993 Apr 20.
Article in English | MEDLINE | ID: mdl-20820360

ABSTRACT

The response of two-phase droplets to intense radiant heating is studied to determine the incident power that is required for causing explosive boiling in the liquid phase. The droplets studied consist of strongly absorbing coal particles dispersed in a weakly absorbing water medium. Experiments are performed by confining droplets (radii = 37, 55, and 80 microm) electrodynamically and irradiating them from two sides with pulsed laser beams. Emphasis is placed on the transition region from accelerated droplet vaporization to droplet superheating and explosive boiling. The time scale observed for explosive boiling is more than 2 orders of magnitude longer than published values for pure liquids. The delayed response is the result of energy transfer limitations between the absorbing solid phase and the surrounding liquid.

5.
Acta Derm Venereol ; 69(3): 238-41, 1989.
Article in English | MEDLINE | ID: mdl-2566229

ABSTRACT

Two cases of melanocytic lesion occurring in condylomata acuminata are described. In situ hybridization with human papillomavirus (HPV) DNA probes specific for 6b, 11, 16, 18 revealed positivity with HPV6 and 11, in the non-dysplastic condylomata, and HPV 18 positivity in the case showing severe dysplasia. The HPV localization was confined to the superficial parakeratotic zones, remote from the melanocytic proliferation. The relationship between human papillomavirus and the melanocytic lesions is discussed.


Subject(s)
Condylomata Acuminata/pathology , Melanocytes/pathology , Nucleic Acid Hybridization , Vulvar Neoplasms/pathology , Adolescent , Adult , Biopsy , Cell Division , Condylomata Acuminata/microbiology , DNA Probes, HPV , Female , Humans , Hyperplasia/pathology , Vulvar Neoplasms/microbiology
6.
SELECTION OF CITATIONS
SEARCH DETAIL
...